{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 41,
  "pageCount": 58,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "market_landscape",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide uses stacked bar charts to show ranking preferences (Top 1, 2, 3) for destinations and simple bar charts for decision factors.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "bar_chart_horizontal",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/41",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.58,
        "w": 0.46,
        "x": 0.5,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Key considerations on choosing clinical trial destination outside China",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd488f72-51d6-4102-8f60-58c9338b926c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.58,
        "w": 0.43,
        "x": 0.037,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Evaluation of clinical trial destination attractiveness outside China",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afe0fcf6-0b83-4c5e-abcc-c28c8016a409",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.037,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Note: *Survey question (for Chinese biopharmas): Please select and rank the top 3 countries that are most attractive for conducting overseas clinical trials. **Survey question (for Chinese biopharmas): What are the main reasons that you choose Top 1 clinical trial destination country in the last question?",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59c4302e-b4e1-4641-b17a-34a177d1d9eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.12,
        "x": 0.31,
        "y": 0.775
      },
      "kind": "legend",
      "text": "Top 1, Top 2, Top 3",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb575a3c-30c0-40a2-8517-d6d29713133e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Percent of respondents: 81",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-f67c51409333",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.037,
        "y": 0.06
      },
      "kind": "title",
      "text": "U.S., Australia and Europe are the most attractive destinations outside China for Chinese biopharmas, considering MNC collaboration, clinical trial duration and speed-to-market",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d37287f-45a4-418f-be51-3a7582ba4368",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.037,
        "y": 0.035
      },
      "kind": "title",
      "text": "Globalization of Chinese Biopharma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05df3d0e-1f2d-4d98-8d71-93b2d9aec87b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Percent of respondents",
      "numberRaw": "81",
      "numberKind": "plain",
      "actionTitle": "U.S., Australia and Europe are the most attractive destinations outside China for Chinese biopharmas, considering MNC collaboration, clinical trial duration and speed-to-market",
      "calloutText": null,
      "numberScale": null,
      "numberValue": 81,
      "metricFamily": "survey_sentiment",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}